ALK B — Alk-Abello A/S Share News
0.000.00%
Last trade - 00:00- DKK51.65bn
- DKK50.34bn
- DKK6.31bn
Brief: Alk-Abello Says Phase 3 Clinical Trial Meets Primary Endpoint
Refinitiv Newscasts - UK Day Ahead: As the world's central bankers gather investors await clues on future policy
Alk-Abello jumps after Q2 beat on strong tablet sales in Japan
Brief: ALK-Abello Narrows FY Revenue Outlook
Brief: ALK-Abello Q2 Revenue DKK 1,135 Million
ALK shares slump as CEO change adds to uncertainty
Brief: ALK-Abello Announces CEO Change At End-2023
Brief: Large Phase 3 Clinical Trial Successfully Meets Primary Endpoint, Confirming The Potential Of ALK's House Dust Mite Tablet In Young Children
Brief: Alk-Abello Says Phase 3 Clinical Trial For HDM Tablet Meets Primary Endpoint
Brief: ALK-Abello Q1 Tablet Sales Increased Overall By 1% To DKK 581 Mln
ALK-Abello hits bottom of STOXX as Q1 European tablet sales disappoint
Brief: ALK Reports Revenue Increase Of 7% In Local Currencies To DKK 1,234 Mln in Q1 2023
Brief: ALK-Abello Posts Q1 Revenue of DKK 1,234 Million
Europe Research Roundup: Hill & Smith, L'Oreal, Segro
Brief: ALK-Abello's Regulatory Filing For Allergy Tablet Is Accepted For Review In China
Brief: Alk-Abello Sees 2023 EBIT Margin At 13-15%
Brief: ALK-Abello Q4 Revenue Slightly Beats Consensus
Brief: U.S. FDA Approves Alk's Odactra® (House Dust Mite Allergen Extract) Tablet For Sublingual Use As Immunotherapy For Adolescents
Refinitiv Newscasts - BVTV: Pricey Danish enzymes